RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...

UBS analyst Susy Tibaldi updated the financial outlook for EssilorLuxottica SA (EL:FP) (OTC: OTC:ESLOY), increasing the price ...

Imposing higher capital requirements on UBS as a systemically relevant bank will usher in higher costs for companies and ...

Bonnici was a managing director at RBC and led several high-profile deals across infrastructure and technology during his ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

Brian McGill and Michael Hyser operate as Johns Creek Financial along with support-staff members Stacie Alexander and Alexis ...

In a report released today, Nik Modi from RBC Capital maintained a Hold rating on Clorox (CLX – Research Report), with a price target of ...

Michael Baumrin joined RBC Capital Markets in 2008 as a Managing Director in the New York ... For the prior nine years, Mr. Baumrin served as Manager of UBS’s Housing Group, which was the number one ...

Australian shares are poised to rise with inflation data awaited. Boeing surged, Nvidia rebounded and Apple extended its recovery. Follow updates here.

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $36.2 which represents a decrease of $-0.35 or -0.96% from the prior close of $36.55. The stock opened at $36.76 and touched a low ...